EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

MicroRNA-206 as a potential cholesterol-lowering drug is superior to statins in mice

Chao Li, Jing Tian, Ningning Liu, David Song, Clifford J Steer, Qinghua Han, Guisheng Song

Journal of Lipid Research · 2024

DOI: 10.1016/j.jlr.2024.100576 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Lipid Research, 2024. Verfasst von Chao Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The First Hospital of Shanxi Medical University, Taiyuan City, China; The First College of Clinical Medicine, Shanxi Medica…. Hauptthemen laut MEDLINE: MicroRNAs, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Cholesterol. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hypercholesterolemia is frequently intertwined with hepatosteatosis, hypertriglyceridemia, and hyperglycemia. This study is designed to assess the therapeutic efficacy of miR-206 in contrast to statins in the context of managing hypercholesterolemia in mice. We previously showed that miR-206 is a potent inhibitor of de novo lipogenesis (DNL), cholesterol synthesis, and gluconeogenesis in mice. Given that these processes occur within hepatocytes, we employed a mini-circle (MC) system to deliver miR-206 specifically to hepatocytes (designated as MC-miR-206). A single intravenous injection of MC-miR-206 maintained high levels of miR-206 in the liver for at least two weeks, thereby maintaining suppression of hepatic DNL, cholesterol synthesis, and gluconeogenesis. MC-miR-206 significantly reduced DNA damage, endoplasmic reticulum and oxidative stress, and hepatic toxicity. Therapeutically, both MC-miR-206 and statins significantly reduced total serum cholesterol and triglycerides as well as LDL cholesterol and VLDL cholesterol in mice maintained on the normal chow and high-fat high-cholesterol diet. MC-miR-206 reduced liver weight, hepatic triglycerides and cholesterol, and blood glucose, while statins slightly increased hepatic cholesterol and blood glucose and failed to affect levels of liver weight and hepatic triglycerides. Mechanistically, miR-206 alleviated hypercholesterolemia by inhibiting hepatic cholesterol synthesis, while statins increased HMGCR activity, hepatic cholesterol synthesis, and fecal-neutral steroid excretion. MiR-206 facilitates the regression of hypercholesterolemia, hypertriglyceridemia, hyperglycemia, and hepatosteatosis. MiR-206 outperforms statins by reducing hyperglycemia, hepatic cholesterol levels, and hepatic toxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsHydroxymethylglutaryl-CoA Reductase InhibitorsCholesterolAnimalsMiceMaleLiverAnticholesteremic AgentsHypercholesterolemiaMice, Inbred C57BLHepatocytesLipogenesis

Stichwörter der Autor:innen

MAFLDadverse effectscholesterol-lowering medicationshypercholesterolemiamicroRNAstatins

Substanzen

MicroRNAsHydroxymethylglutaryl-CoA Reductase InhibitorsMirn206 microRNA, mouseCholesterolAnticholesteremic Agents

Autor:innen und Institutionen

  • Department of Cardiology, The First Hospital of Shanxi Medical University, Taiyuan City, China; The First College of Clinical Medicine, Shanxi Medical University, Taiyuan City, China.
  • Department of Cardiology, The First Hospital of Shanxi Medical University, Taiyuan City, China.
  • Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
  • Department of Cardiology, The First Hospital of Shanxi Medical University, Taiyuan City, China. Electronic address: sygqh@sohu.com.
  • Department of Medicine, University of Minnesota, Minneapolis, MN, USA. Electronic address: gsong@umn.edu.

Zitieren

APA

Li, C., Tian, J., Liu, N., Song, D., Steer, C. J., Han, Q., & Song, G. (2024). MicroRNA-206 as a potential cholesterol-lowering drug is superior to statins in mice. Journal of Lipid Research. https://doi.org/10.1016/j.jlr.2024.100576

Vancouver

Li C, Tian J, Liu N, Song D, Steer CJ, Han Q, et al. MicroRNA-206 as a potential cholesterol-lowering drug is superior to statins in mice. Journal of Lipid Research. 2024. doi:10.1016/j.jlr.2024.100576

BibTeX
@article{Li2024,
  author = {Li, Chao and Tian, Jing and Liu, Ningning and Song, David and Steer, Clifford J and Han, Qinghua and Song, Guisheng},
  title = {MicroRNA-206 as a potential cholesterol-lowering drug is superior to statins in mice},
  journal = {Journal of Lipid Research},
  year = {2024},
  doi = {10.1016/j.jlr.2024.100576}
}
Kostenlos starten →